Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity

Jubran,Ritta; Saar-Ray,Moran; Wawruszak,Anna; Ziporen,Lea; Donin,Natalie; Bairey,Osnat; Fishelson,Zvi

doi:10.3892/ijo.2020.5101

Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity

Authors:
- Ritta Jubran
- Moran Saar-Ray
- Anna Wawruszak
- Lea Ziporen
- Natalie Donin
- Osnat Bairey
- Zvi Fishelson
View Affiliations

Affiliations: Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel, Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin 20-093, Poland, Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva 49100, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
Published online on: July 16, 2020 https://doi.org/10.3892/ijo.2020.5101
Pages: 1013-1026

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer cells have developed numerous strategies to maintain their proliferative capacity and to withstand different kinds of stress. The mitochondrial stress‑70 protein named glucose regulated protein 75 (GRP75), also known as mortalin, is an intriguing cancer pro‑survival factor. It is constitutively expressed in normal tissues but is upregulated in many tumors, and was shown to be a cancer prognostic biomarker. Mortalin is an inhibitor of complement‑dependent cytotoxicity (CDC) and may therefore protect cells from antibody‑based immunotherapy. To target mortalin for cancer therapy, our laboratory designed several mortalin mimetic peptides with sequences predicted to be involved in mortalin binding to its client proteins. The peptides were synthesized with a C‑terminal transactivator of transcription sequence. By using cell death methodologies, the mechanism of action of the mortalin mimetic peptides on cancer cells was studied. Two peptides in particular, Mot‑P2 and Mot‑P7, were found to be highly toxic to lymphoma and ovarian, breast and prostate carcinoma cells. The analysis of their mode of action revealed that they may induce, within minutes, plasma membrane perturbations and mitochondrial stress. Furthermore, Mot‑P2 and Mot‑P7 activated necrotic cell death, leading to plasma membrane perforation, mitochondrial inner membrane depolarization and decrease in ATP level. In addition, Mot‑P7, but not Mot‑P2, required extracellular calcium ions to fully mediate cell death and was partially inhibited by plasma membrane cholesterol. At sub‑toxic concentrations, the two peptides moderately inhibited cancer cell proliferation and blocked cell cycle at G2/M. Both peptides may bind intracellularly to mortalin and/or a mortalin‑binding protein, hence knocking down mortalin expression reduced cell death. Combining treatment with Mot‑P2 or Mot‑P7 and CDC resulted in increased cell death. This study identified highly cytotoxic mortalin mimetic peptides that may be used as monotherapy or combined with complement‑activating antibody therapy to target mortalin for precision cancer therapy.

View Figures

View References

1	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ran Q, Wadhwa R, Kawai R, Kaul SC, Sifers RN, Bick RJ, Smith JR and Pereira-Smith OM: Extramitochondrial localization of mortalin/mthsp70/PBP74/GRP75. Biochem Biophys Res Commun. 275:174–179. 2000. View Article : Google Scholar : PubMed/NCBI
3	Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR and Kaul SC: Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res. 274:246–253. 2002. View Article : Google Scholar : PubMed/NCBI
4	Dundas SR, Lawrie LC, Rooney PH and Murray GI: Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol. 205:74–81. 2005. View Article : Google Scholar
5	Takano S, Wadhwa R, Yoshii Y, Nose T, Kaul SC and Mitsui Y: Elevated levels of mortalin expression in human brain tumors. Exp Cell Res. 237:38–45. 1997. View Article : Google Scholar
6	Ando K, Oki E, Zhao Y, Ikawa-Yoshida A, Kitao H, Saeki H, Kimura Y, Ida S, Morita M, Kusumoto T, et al: Mortalin is a prognostic factor of gastric cancer with normal p53 function. Gastric Cancer. 17:255–262. 2014. View Article : Google Scholar
7	Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR and Kaul SC: Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer. 118:2973–2980. 2006. View Article : Google Scholar : PubMed/NCBI
8	Rozenberg P, Kocsis J, Saar M, Prohászka Z, Füst G and Fishelson Z: Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer. Int J Cancer. 133:514–518. 2013. View Article : Google Scholar : PubMed/NCBI
9	Jubran R, Kocsis J, Garam N, Maláti É, Gombos T, Barabás L, Gráf L, Prohászka Z and Fishelson Z: Circulating mitochondrial stress 70 protein/mortalin and cytosolic Hsp70 in blood: Risk indicators in colorectal cancer. Int J Cancer. 141:2329–2335. 2017. View Article : Google Scholar : PubMed/NCBI
10	Kaul SC, Deocaris CC and Wadhwa R: Three faces of mortalin: A housekeeper, guardian and killer. Exp Gerontol. 42:263–274. 2007. View Article : Google Scholar
11	Voisine C, Craig EA, Zufall N, von Ahsen O, Pfanner N and Voos W: The protein import motor of mitochondria: Unfolding and trapping of preproteins are distinct and separable functions of matrix Hsp70. Cell. 97:565–574. 1999. View Article : Google Scholar : PubMed/NCBI
12	Pilzer D and Fishelson Z: Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int Immunol. 17:1239–1248. 2005. View Article : Google Scholar : PubMed/NCBI
13	Pilzer D, Saar M, Koya K and Fishelson Z: Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity. Int J Cancer. 126:1428–1435. 2010.
14	Saar Ray M, Moskovich O, Iosefson O and Fishelson Z: Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity. J Biol Chem. 289:15014–15022. 2014. View Article : Google Scholar : PubMed/NCBI
15	Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:1189–1193. 1988. View Article : Google Scholar : PubMed/NCBI
16	Raucher D and Ryu JS: Cell-penetrating peptides: Strategies for anticancer treatment. Trends Mol Med. 21:560–570. 2015. View Article : Google Scholar : PubMed/NCBI
17	Darzynkiewicz Z, Juan G and Bedner E: Determining cell cycle stages by flow cytometry. Curr Protoc Cell Biol Chapter. 8(Unit 8): 42001.
18	Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, Steele GD Jr and Chen LB: Intracellular heterogeneity in mito-chondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA. 88:3671–3675. 1991. View Article : Google Scholar
19	Vivès E, Brodin P and Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 272:16010–16017. 1997. View Article : Google Scholar : PubMed/NCBI
20	Nagata S: Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol. 36:489–517. 2018. View Article : Google Scholar : PubMed/NCBI
21	Hirt UA and Leist M: Rapid, noninflammatory and PS-dependent phagocytic clearance of necrotic cells. Cell Death Differ. 10:1156–1164. 2003. View Article : Google Scholar : PubMed/NCBI
22	Caserta TM, Smith AN, Gultice AD, Reedy MA and Brown TL: Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 8:345–352. 2003. View Article : Google Scholar : PubMed/NCBI
23	Zhivotovsky B and Orrenius S: Calcium and cell death mechanisms: A perspective from the cell death community. Cell Calcium. 50:211–221. 2011. View Article : Google Scholar : PubMed/NCBI
24	Mason AJ, Marquette A and Bechinger B: Zwitterionic phospholipids and sterols modulate antimicrobial peptide-induced membrane destabilization. Biophys J. 93:4289–4299. 2007. View Article : Google Scholar : PubMed/NCBI
25	Prenner EJ, Lewis RNAH, Jelokhani-Niaraki M, Hodges RS and McElhaney RN: Cholesterol attenuates the interaction of the antimicrobial peptide gramicidin S with phospholipid bilayer membranes. Biochim Biophys Acta. 1510:83–92. 2001. View Article : Google Scholar : PubMed/NCBI
26	Moskovich O, Herzog LO, Ehrlich M and Fishelson Z: Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis. J Biol Chem. 287:19904–19915. 2012. View Article : Google Scholar : PubMed/NCBI
27	Liu Y, Liu W, Song XD and Zuo J: Effect of GRP75/mthsp70/PBP74/mortalin overexpression on intracellular ATP level, mitochondrial membrane potential and ROS accumulation following glucose deprivation in PC12 cells. Mol Cell Biochem. 268:45–51. 2005. View Article : Google Scholar : PubMed/NCBI
28	Sun SY: N-acetylcysteine, reactive oxygen species and beyond. Cancer Biol Ther. 9:109–110. 2010. View Article : Google Scholar
29	Moskovich O and Fishelson Z: Quantification of complement C5b-9 binding to cells by flow cytometry. The Complement System: Methods and Protocols. 1100th edition. Gadjeva M: Humana Press; Totowa, NJ: pp. 103–108. 2014, View Article : Google Scholar
30	Bhakdi S, Tranum-Jensen J and Klump O: The terminal membrane C5b-9 complex of human complement. Evidence for the existence of multiple protease-resistant polypeptides that form the trans-membrane complement channel. J Immunol. 124:2451–2457. 1980.PubMed/NCBI
31	Koya K, Li Y, Wang H, Ukai T, Tatsuta N, Kawakami M, Shishido and Chen LB: MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res. 56:538–543. 1996.PubMed/NCBI
32	Kunzelmann-Marche C, Freyssinet JM and Martínez MC: Regulation of phosphatidylserine transbilayer redistribution by store-operated Ca2+ entry: Role of actin cytoskeleton. J Biol Chem. 276:5134–5139. 2001. View Article : Google Scholar
33	Heuck AP, Moe PC and Johnson BB: The cholesterol-dependent cytolysin family of gram-positive bacterial toxins. Subcell Biochem. 51:551–577. 2010. View Article : Google Scholar : PubMed/NCBI
34	Won A, Ruscito A and Ianoul A: Imaging the membrane lytic activity of bioactive peptide latarcin 2a. Biochim Biophys Acta. 1818:3072–3080. 2012. View Article : Google Scholar : PubMed/NCBI
35	Del Gaizo V, MacKenzie JA and Payne RM: Targeting proteins to mitochondria using TAT. Mol Genet Metab. 80:170–180. 2003. View Article : Google Scholar : PubMed/NCBI
36	Palmer AC and Sorger PK: Combination cancer therapy can confer benefit via patient-topatient variability without drug additivity or synergy. Cell. 171:1678–1691.e13. 2017. View Article : Google Scholar
37	Foucquier J and Guedj M: Analysis of drug combinations: Current methodological landscape. Pharmacol Res Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
38	Kurrikoff K, Aphkhazava D and Langel Ü: The future of peptides in cancer treatment. Curr Opin Pharmacol. 47:27–32. 2019. View Article : Google Scholar : PubMed/NCBI
39	Guidotti G, Brambilla L and Rossi D: Peptides in clinical development for the treatment of brain tumors. Curr Opin Pharmacol. 47:102–109. 2019. View Article : Google Scholar : PubMed/NCBI
40	Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B and Yeger H: Combination therapy in combating cancer. Oncotarget. 8:38022–38043. 2017. View Article : Google Scholar : PubMed/NCBI